Multi‐fluorine labeled indanone derivatives as potential MRI imaging probes for β‐Amyloid plaques. (25th November 2022)
- Record Type:
- Journal Article
- Title:
- Multi‐fluorine labeled indanone derivatives as potential MRI imaging probes for β‐Amyloid plaques. (25th November 2022)
- Main Title:
- Multi‐fluorine labeled indanone derivatives as potential MRI imaging probes for β‐Amyloid plaques
- Authors:
- Dai, Yaqian
Fang, Tangni
Xu, Yuanhong
Jiang, Taoshan
Qiao, Jinping - Abstract:
- Abstract: In order to realize the early diagnosis of Alzheimer's disease (AD), we designed and synthesized a series of multi‐fluorine labeled indanone derivatives based on indanone which could target β‐amyloid (Aβ). Through the in vitro staining experiment and affinity experiment, we selected 7d out, and then evaluated it through other in vivo and in vitro experiments. The staining of AD human brain adjacent sections revealed that compound 7d could bind to Aβ plaques with high affinity. In the in vitro binding assay, 7d showed a balanced affinity with Aβ1–40 ( K d = 367 ± 13) and Aβ1–42 ( K d = 384 ± 56). Also, 7d exhibited a low toxicity (LD50 > 50 mg/kg) and an excellent ability to pass through the blood–brain barrier (Log p = 3.87). The biodistribution experiment in mice showed that 7d reached the highest brain uptake after 1 h of tail vein injection and cleared after 24 h. A low concentration of 7d (1.875 mg/ml) showed a strong imaging ability (19F‐weighted mode), and the imaging capability increased with the increasing of concentration. All the results showed that 7d could provide a feasible solution for the early diagnosis of AD under non‐radioactive condition. Abstract : We synthesized a series of multi‐fluorine labeled indanone derivatives based on the indanone; we selected 7d out through the in vitro staining experiment and affinity experiment, then evaluated it through other in vivo and in vitro experiments.
- Is Part Of:
- Chemical biology & drug design. Volume 101:Number 3(2023)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 101:Number 3(2023)
- Issue Display:
- Volume 101, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 101
- Issue:
- 3
- Issue Sort Value:
- 2023-0101-0003-0000
- Page Start:
- 650
- Page End:
- 661
- Publication Date:
- 2022-11-25
- Subjects:
- Alzheimer's disease -- indanone -- molecular imaging -- MRI -- β‐Amyloid
Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.14162 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 25760.xml